A novel multivalent tuberculosis vaccine confers protection in a mouse model of tuberculosis.
Mycobacterium tuberculosis infects one third of the world's population. Due to variable efficacy of the Bacille Calmette Guerin (BCG) vaccine, development of novel TB vaccines remains a priority. Here, we demonstrate the protective efficacy of a novel multivalent DNA vaccine, which contains 15 synthetic antigens targeting the Mtb ESX secretion system.
a Department of Molecular Microbiology , Washington University in St. Louis , St. Louis , MO , USA.
Kristin L
KL
Griffiths
b Department of Pathology and Laboratory Medicine , University of Pennsylvania School of Medicine , Philadelphia , PA , USA.
Daniel O
DO
Villarreal
b Department of Pathology and Laboratory Medicine , University of Pennsylvania School of Medicine , Philadelphia , PA , USA.
David B
DB
Weiner
a Department of Molecular Microbiology , Washington University in St. Louis , St. Louis , MO , USA.
Shabaana A
SA
Khader
D000818:Animals; D004195:Disease Models, Animal; D006801:Humans; D008810:Mice, Inbred C57BL; D009169:Mycobacterium tuberculosis / Q000276:immunology*; D014376:Tuberculosis / Q000276:immunology / Q000517:prevention & control*; D032581:Tuberculosis Vaccines / Q000276:immunology* / Q000302:isolation & purification*
D032581:Tuberculosis Vaccines
DNA vaccine; Tuberculosis; vaccine